Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Open to people ages 18 years and up

Patients must meet all of the following inclusion criteria in order to be eligible to participate in this study:

• Adults (Aged ≥ 18 years)
• Histologically confirmed endometrial cancer (endometrioid, serous, undifferentiated, or carcinosarcoma sub-types) that is TP53 wild type by central NGSHistologically confirmed EC including endometrioid, serous, undifferentiated, and carcinosarcoma
• Must have completed at least 12 weeks of platinum-based chemotherapy (with or without immune checkpoint inhibitors), with a confirmed partial or complete response according to RECIST v1.1
• Must be able to initiate C1D1 within 3-8 weeks after last platinum dose
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Adequate bone marrow function and organ function

Patients meeting any of the following exclusion criteria are not eligible to participate in this study:

• Uterine sarcomas, clear cell or small cell carcinoma with neuroendocrine differentiation
• Palliative radiotherapy administered within 14 days of intended C1D1
• Any gastrointestinal dysfunction that could interfere with the absorption of oral study therapy
• Serious psychiatric or medical conditions that could interfere with study participation or would make study involvement unreasonably hazardous
• Previous treatment with an XPO1 inhibitor
• Stable disease or disease progression after platinum-based chemotherapy
• Pregnancy, breastfeeding, or other legal/ethical restrictions to trial participation
• Known dMMR/MSI-H EC tumors that are medically eligible to receive an immune checkpoint inhibitor